Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Exousia Pro's Enterprise Value for the quarter that ended in Jan. 2021 was $20.00 Mil.
Exousia Pro's EBIT for the trailing twelve months (TTM) ended in Jan. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exousia Pro EV-to-EBIT Related Terms
Exousia Pro EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Exousia Pro's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Exousia Pro's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exousia Pro EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exousia Pro's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Exousia Pro's EV-to-EBIT falls into.
Exousia Pro's current Enterprise Value is $0.60 Mil.
Exousia Pro's EBIT for the trailing twelve months (TTM) ended in Jan. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exousia Pro (MAJI) has a EV-to-EBIT of -1.15 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Exousia Pro and its competitors.
Is Exousia Pro's EV-to-EBIT too high?
Exousia Pro's current EV-to-EBIT is -1.15.
How does Exousia Pro's EV-to-EBIT compare to HCCH and GRNV?
Exousia Pro's EV-to-EBIT of -1.15 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 15.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.71, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Exousia Pro and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exousia Pro's current EV-to-EBIT is -1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current EV-to-EBIT of -1.15. The current EV-to-EBIT is -1.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Exousia Pro (MAJI), the current EV-to-EBIT is -1.15 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAJI has been successfully added to your 
